Glucosarcopenia, or sarcopenia coexisting with diabetes, is a common condition. Caused by various factors, including poor glucose control, as well as some glucoselowering therapies, sarcopenia negatively impacts quality of life and long-term health. Nandrolone, or 19- nortestosterone, is a selective anabolic receptor modulator (SARM), classified as an anabolic-androgenic steroid (AAS). A review of its pharmacological properties suggests that it may be used as therapy for sarcopenia, along with medical nutrition therapy and resistance exercise training. This review suggests a practical and pragmatic approach towards ensuring safe and smart usage of nandrolone in glucosarcopenia management.